Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study

Chemotherapeutic multidrug resistance (MDR) is a significant challenge to overcome in clinic practice. Several mechanisms contribute to MDR, one of which is the augmented drug efflux induced by the upregulation of ABCB1 in cancer cells. Regorafenib, a multikinase inhibitor targeting the RAS/RAF/MEK/...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Lett
Glavni autori: Wang, Yi-Jun, Zhang, Yun-Kai, Zhang, Guan-Nan, Al Rihani, Sweilem B., Wei, Meng-Ning, Gupta, Pranav, Zhang, Xiao-Yu, Shukla, Suneet, Ambudkar, Suresh V., Kaddoumi, Amal, Shi, Zhi, Chen, Zhe-Sheng
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507680/
https://ncbi.nlm.nih.gov/pubmed/28302530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2017.03.011
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items